Conference abstract · 15 Sep 2015
Conference abstractPublished 24 Aug 2015
When beta therapy fails – Is alpha therapy a solution?
Brookhaven National Lab Upton, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Actinium-225 (225Ac) has a half life of 9.92 days, decaying through multiple intermediate nuclei to a daughter isotope Bismuth-213 (213Bi) with a half life of 45 min. Both isotopes have been investigated for targeted alpha therapy. Researchers have shown 213Bi DOTATOC can shrink tumors in patients that had previously not responded to similar treatments with the beta emitting isotopes 90Y and 177Lu . The United States Department of Energy (US DOE) supplies purified 225Ac from a generator system associated with the parent isotope 229Th, but this approach does not supply enough 225Ac for the applications associated with both 225Ac and 213Bi. To meet this demand the US DOE has initiated a Tri-lab (Los Alamos-Brookhaven-Oak Ridge National Laboratories) effort to develop 225Ac by irradiation of a thorium target with high energy (90-200 MeV) protons. One of the main challenges associated with this production route is isolation of 225Ac from bulk thorium and other radionuclides (~400) formed as a result of fission and other nuclear reactions. In targeted alpha therapy with 225Ac the retention of the multiple daughters of 225Ac at the target site has been problematic. A chemical method to produce a targeting nanochelator to: capture 225Ac, retain the daughters of alpha decay, and target tumors will be discussed.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2015
When beta therapy fails – Is alpha therapy a solution? Actinium-225 production and applications
Research article · 23 Sep 2016
Stromal Derived Factor 1 alpha (SDF-1a) in a Dual Therapy with the DPP-4 Inhibitor 1 Vildagliptin does not Enhance Beta Cell Function but Improves Glucose Clearance after Oral Glucose in Streptozotocin Diabetic Mice
Conference abstract
Multifunctional nanoparticles composed of a mixed ferrite core and a mesoporous silica shell for RGD peptide to target alpha (v) beta (3) integrin in cancer therapy and diagnosis
Short communication · 29 Aug 2025
Rescue therapies when standard treatment fails
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Jonathan Fitzsimmons”
